Japanese drug major Eisai (TYO: 4523) on Friday said it has partnered with the USA's Halozyme Therapeutics (Nasdaq: HALO) for early stage combination drug trial to treat advanced breast cancer.
The company said it will evaluate the impact of its Halaven (eribulin) and Halozyme’s drug candidate PEGPH20 (PEGylated recombinant human hyaluronidase) to treat metastatic breast cancer.
Under the terms of the deal, both the companies will jointly conduct and share the costs of a Phase Ib/II clinical study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze